Y-mAbs acquired by Perseus BidCo US; tender offer completed at $8.60/share, ~$413M total

Y-mAbs Therapeutics, Inc.

Approximately 39.8M shares (~87.22%) tendered; Purchaser accepted all validly tendered shares.
Merger closed Sep 16; each outstanding share (except excluded) converted to $8.60 cash.
Aggregate consideration ~$413M funded via cash on hand and short-term financing.
Shares to be delisted from Nasdaq; company will file Form 15 to suspend reporting obligations.
All prior directors and officers resigned; new board and officers appointed (Vanessa Wolfeler, Robert Duffield, Daniel Dolan).

item 2.01item 3.01item 3.03item 5.01item 5.02item 5.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.